RT Journal Article
SR Electronic
T1 Serological surveillance reveals a high exposure to SARS-CoV-2 and altered immune response among COVID-19 unvaccinated Cameroonian individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.24.23294559
DO 10.1101/2023.08.24.23294559
A1 Moguem Soubgui, Arlette Flore
A1 Ndeme Mboussi, Wilfred Steve
A1 Kojom Foko, Loick Pradel
A1 Embolo Enyegue, Elisée Libert
A1 Koanga Mogtomo, Martin Luther
YR 2023
UL http://medrxiv.org/content/early/2023/08/25/2023.08.24.23294559.abstract
AB Background Surveillance of COVID-19/SARS-CoV-2 dynamics is crucial to understanding natural history and providing insights into the population’s exposure risk and specific susceptibilities. This study investigated the seroprevalence of SARS-CoV-2 antibodies, its predictors, and immunological status among unvaccinated patients in Cameroon.Materials and Methods A multicentre cross-sectional study was conducted between January and September 2022 in the town of Douala. Patients were consecutively recruited, and data of interest were collected using a questionnaire. Blood samples were collected to determine Immunoglobin titres (IgM and IgG) by ALFA, CD4+ cells by flow cytometry, and interferon gamma (IFN-γ) and interleukin-6 (IL-6) by ELISA.Results A total of 342 patients aged 41.5 ± 13.9 years were included. Most participants (75.8%) were asymptomatic. The overall prevalence of IgM and IgG was 49.1% and 88.9%, respectively. Ageusia and anosmia have displayed the highest positive predictive values (90.9% and 82.4%) and specificity (98.9% and 98.3%). The predictors of IgM seropositivity were being aged 60 – 70 years (aOR = 0.54, p = 0.02) and ageusia (aOR = 9.31, p = 0.01), whereas those of IgG seropositivity included health facility (aOR = 0.23, p = 0.02) and ageusia (aOR = 0.21, p = 0.04). CD4+, IFN-γ, and IL-6 were impaired in seropositive individuals, with a confounding role of socio-demographic factors or comorbidities.Conclusion Although the WHO declared the end of COVID-19 as a public health emergency, the findings of this study indicate the need for continuous surveillance to adequately control the disease in Cameroon.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An ethical authorization was issued by the institutional review board of the University of Douala (N? 2945 CEI-UDo/12/2021/T), Littoral Health Regional Delegation (N? 0038/ AAR/MINSANTE/DRSPL/BCASS), and Douala Laquintinie Hospital (N? 08179/AR/MINSANTE/DHL).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are within the manuscript and supporting files, and relevant data underlying the results presented in the study has been filed in the Dryad repository and available from https://doi.org/10.5061/dryad.1vhhmgr00.95%CIConfidence interval at 95%ALFAEnzyme-linked immunofluorescent assayANOVAAnalysis of varianceaORAdjusted odds ratiocORCrude odds ratioaRRAdjusted risk ratioBMIBody mass indexCDCluster of differentiationcRRCrude risk ratioCOVID–19Coronavirus disease 2019dfDegree of freedomELISAEnzyme-linked immunosorbent assayIFNInterferonIgImmunoglobulinHIVHuman immunodeficiency virusPPVPositive predictive valueROCReceiver operating curveRT-qPCRRetrotranscriptase quantitative polymerase chain reactionSARS–CoV–2Severe acute respiratory syndrome coronavirus 2SDStandard deviationSEStandard errorSpSpecificity